New data on quality of life and long-term prognosis after ICD implantation for primary prevention was recently published in the New England Journal of Medicine. Join Drs Bhatt, Harrington, and Prystowsky as they review this new data and discuss the clinical context of these studies.
For all the debates on rate vs rhythm control, contemporary analyses show little change in atrial fibrillation (AF) mortality rates in the past 20 years. Will recent developments, including novel pharmacologic agents and advances in catheter ablation, translate into meaningful clinical benefit for patients? Drs Camm, Falk, Knecht, and Hohnloser each give presentations on key issues relating to the contemporary management of patients with AF.
The rate vs rhythm AF trials suggest that rhythm-managed AF patients experience more strokes possibly due to cessation of warfarin in patients with unrecognized, asymptomatic AF. Stuart Connolly presents the ESC late-breaking ATHENA findings that challenge this viewpoint and Drs Fox, Dorian, and Steg discuss the implications and possible mechanisms.
Hypertrophic cardiomyopathy (HCM) is a complex but common genetic heart disease that affects nearly one in 500 people in the US and often goes undiagnosed. It is characterized by abnormal thickening of the heart's chamber walls and is the most common cause of sudden cardiac death in people under age 30. Please take a moment to share your perspective on the role of HCM management with theheart.org.
Join Drs Linde, Daubert and Gold in an intriguing discussion on the impact of cardiac resynchronization therapy on remodeling and disease progression, with a review of new data by Dr Abraham.
In the ATHENA trial, an investigational amiodarone congener prolonged time to first CV hospitalization or death in elderly AF patients. The electrophysiologists have had their say what are the implications for the rest of the cardiology community? Hear Drs Alpert, Steg and Topol give the non-EP perspective.
The ATHENA trial was a late-breaker at Heart Rhythm 2008. Join Drs Prystowsky, Hohnloser, Ruskin and Waldo as they discuss pharmacologic challenges in AF management.
